CRISPR Therapeutics AG Net Income

The latest net income for CRSP is $-450M as of June 2026. That compares with $-470M in the prior-year period — up 3.6% year over year. That is below the Healthcare sector average of $16B. Investors often review this figure alongside CRISPR Therapeutics AG's historical trend and sector peers before judging valuation or financial health.

Over the past year, CRSP's net income moved from $-470M to $-450M — a 3.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CRISPR Therapeutics AG's operating scale or balance-sheet position.

Against Healthcare companies, CRSP currently prints $-450M for net income, while the sector average sits near $16B. That is roughly 102.8% below the sector mean. Large gaps often invite a closer look at CRISPR Therapeutics AG's growth, margins, and balance sheet.

A net income figure of $-450M for CRSP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $16B. Explore the charts below for those layers of context.

After noting CRSP's net income ($-450M), review year-over-year change from $-470M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.